Jonathan Savidge
CEO
Jonathan has over 25 years of experience in the biotech/pharma industry focused on building strategic partnerships to progress development of new therapeutics. Prior to joining Kynos, Jonathan was founding CEO of Syndesi Therapeutics, overseeing the development of a small molecule for CNS indications and leading the company to a $1BN acquisition deal with AbbVie in March 2022. Jonathan has previously worked in business and corporate development roles at companies including Evotec, Bicycle Therapeutics and Proximagen. He has led numerous varied partnership deals with pharma and biotech companies across both pre-clinical and clinical stage assets. Jonathan has a PhD in Pharmacology and Neuroscience from the University of Manchester.